nib appoint Chief Financial Officer

Mar 2020

We were privileged to partner with nib (ASX: NHF) in appointing Nick Freeman as Group Chief Financial Officer.

Nick Freeman is a Chartered Accountant with more than 25 years' experience in accounting and finance. He is currently CFO and Company Secretary of Mayne Pharma (ASX: MYX), with responsibility for end-to-end company CFO and Company Secretary responsibilities.

nib Managing Director, Mark Fitzgibbon said following a comprehensive recruitment process he was thrilled to have secured a high calibre and accomplished executive in Nick. "Nick is not only a highly credentialed CFO, but his extensive knowledge of the health sector and financial services as well as experience working for large ASX-listed multi-national organisations makes him a great fit for our team,” Mr Fitzgibbon said.

Nick's appointment comes following the announcement on 23 December 2019, that nib current Group CFO, Michelle McPherson notified the company of her resignation. Michelle will leave the organisation on 20 March 2020, with Glenn Treadwell who is currently nib's CFO Corporate to step into the role of Acting Group CFO until Nick joins nib.

nib also announced a number of senior management changes designed to significantly reduce operating costs and better align the company’s organisational structure with strategic priorities including the creation of its new joint venture with USA based and global health insurer Cigna. David Kan (Group Executive – International Business), Justin Vaughan (Group Executive – Benefits and Provider Relations) and Wendy Lenton (Group Executive – People and Culture) will all be departing nib.

“These roles will be absorbed within nib's existing leadership ranks and we’re fortunate to have a wellspring of emerging talent to ensure we don't miss a beat, he said.

Mr Fitzgibbon said each executive had made an outstanding contribution to nib’s growth and development over recent years.

Nick has been Group CFO and Company Secretary of ASX-listed Mayne Pharma since May 2017. He is a seasoned and transformational CFO having worked as an executive in a number of industries such as healthcare, financial services, consumer, retail and aviation. He has extensive experience in financial and management accounting, mergers and acquisitions, integration management, tax, financial planning and analysis, risk management, treasury and investor relations. Prior to Mayne Pharma, he was CFO – Australia for ANZ Banking Group and earlier as CFO; New Zealand for the Group.